Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy

Kobayashi, Keisuke; Shimizu, Eiji; Hashimoto, Kenji; Mitsumori, Makoto; Koike, Kaori; Okamura, Naoe; Koizumi, Hiroki; Ohgake, Shintaro; Matsuzawa, Daisuke; Zhang, Lin; Nakazato, Michiko; Iyo, Masaomi

doi:10.1016/j.pnpbp.2005.04.010

Cited by 84 publications

(58 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies conducted in patients with major depression have reported that depressive symptom levels were negatively correlated with serum BDNF levels [18]. In contrast, no connection between levels of anxiety symptoms and BDNF in patients with panic disorder and obsessive-compulsive disorder has been reported [25,27]. When our findings are considered, the duration rather than severity of GAD during pregnancy seems to have a stronger effect on fetal circulating BDNF levels.…”

Section: Discussioncontrasting

confidence: 63%

“…In addition, other studies have suggested that patients with schizophrenia [23,24] and obsessive-compulsive disorder [25,26] had lower serum BDNF levels. Kobayashi et al [27] noted that lower BDNF levels were related to poorer response to treatment in patients with panic disorder, although there was no significant difference between patients and controls for BDNF levels.…”

Section: Introductıonmentioning

confidence: 99%

See 1 more Smart Citation

Maternal generalized anxiety disorder during pregnancy and fetal brain development: A comparative study on cord blood brain-derived neurotrophic factor levels

Uğuz

Sönmez

Sahingoz

et al. 2013

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 63%

Section: Introductıonmentioning

confidence: 99%

Maternal generalized anxiety disorder during pregnancy and fetal brain development: A comparative study on cord blood brain-derived neurotrophic factor levels

Uğuz

Sönmez

Sahingoz

et al. 2013

Journal of Psychosomatic Research

View full text Add to dashboard Cite

“…Also, serum BDNF levels of patients with poor response were shown to be significantly lower than those levels of patients with good response. In this sample, however, no significant differences between patients and normal controls were detected (Kobayashi et al 2005). In a large sample of healthy volunteers, an association was found between BDNF serum concentrations and the depression-related personality trait neuroticism (Lang et al 2004a,b).…”

Section: Introductionmentioning

confidence: 71%

Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation

Lang¹,

Bajbouj

Gallinat

et al. 2006

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Nonetheless, a meta-analysis revealed a significant correlation between changes in serum BDNF levels and depression scores following antidepressant treatment (Brunoni et al, 2008), which suggests that serum BDNF levels relate to therapeutic efficacy. Indeed, serum BDNF levels are differentially regulated in 'good' versus 'poor' responders to antidepressant treatments in MDD, following classical (venlafaxine) or atypical antidepressant treatments such as ketamine, exercise or cognitive behavioral therapy (Dreimüller et al, 2012; Haile et al, 2014;Kobayashi et al, 2005;Rojas et al, 2011;Toups et al, 2011). Furthermore, clinical evidence suggests that high serum BDNF levels prior to or early after treatment predict a subsequent positive response to a classical antidepressant (Dreimüller et al, 2012;Mikoteit et al, 2014;Tadić et al, 2011;Wolkowitz et al, 2011).…”

mentioning

confidence: 99%

Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants

Duclot

Kabbaj

2015

Journal of Experimental Biology

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a devastating neuropsychiatric disorder encompassing a wide range of cognitive and emotional dysfunctions. The prevalence of MDD is expected to continue its growth to become the second leading cause of disease burden (after HIV) by 2030. Despite an extensive research effort, the exact etiology of MDD remains elusive and the diagnostics uncertain. Moreover, a marked inter-individual variability is observed in the vulnerability to develop depression, as well as in response to antidepressant treatment, for nearly 50% of patients. Although a genetic component accounts for some cases of MDD, it is now clearly established that MDD results from strong gene and environment interactions. Such interactions could be mediated by epigenetic mechanisms, defined as chromatin and DNA modifications that alter gene expression without changing the DNA structure itself. Some epigenetic mechanisms have recently emerged as particularly relevant molecular substrates, promoting vulnerability or resilience to the development of depressive-like symptoms. Although the role of brainderived neurotrophic factor (BDNF) in the pathophysiology of MDD remains unclear, its modulation of the efficacy of antidepressants is clearly established. Therefore, in this review, we focus on the epigenetic mechanisms regulating the expression of BDNF in humans and in animal models of depression, and discuss their role in individual differences in vulnerability to depression and response to antidepressant drugs. KEY WORDS: BDNF, Epigenetics, Individual differences IntroductionMajor depressive disorder (MDD) is a common debilitating disorder (Bromet et al., 2011) affecting many aspects of the patient's life and family. In addition to its high comorbidity with other neuropsychiatric conditions and increased rate of suicide, depression has a variety of socioeconomic consequences, including low education, unstable employment, reduced work performance and marital dysfunction (Kessler and Bromet, 2013). In 2000, the economic costs of depression in the United States alone were estimated at $83.1 billion, encompassing direct medical costs, suicide-related mortality costs, as well as indirect workplace costs (Greenberg et al., 2003). Moreover, the prevalence of depressive disorders is expected to continue its growth and become by the year 2030 the second leading cause of disease burden among the World Health Organization member states (Mathers and Loncar, 2006). Despite extensive research efforts in past decades, the etiology of REVIEW Department of Biomedical Sciences, Neuroscience Program, Florida State University, Tallahassee, FL 32306, USA.*Author for correspondence (mohamed.kabbaj@med.fsu.edu) depression remains elusive, its diagnosis uncertain and the pharmacotherapy inefficient. Indeed, the antidepressants currently used, which target the monoaminergic pathways, require weeks to months of treatment and exhibit very poor or no response in nearly 50% of patients (Magni et al., 2013;Trivedi et al., 2006;Warden et al., 20...

show abstract

Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy

Cited by 84 publications

References 42 publications

Maternal generalized anxiety disorder during pregnancy and fetal brain development: A comparative study on cord blood brain-derived neurotrophic factor levels

Maternal generalized anxiety disorder during pregnancy and fetal brain development: A comparative study on cord blood brain-derived neurotrophic factor levels

Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation

Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants

Contact Info

Product

Resources

About